SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported Binance security breach has fueled Bitcoin selling and weighed on MSTR, which traders view as a leveraged proxy for Bitcoin; the discussion also centers on Strategys Q3 revenue miss, earnings driven largely by Bitcoin valuation gains, and its CFO transition. Bears warn of further downside and dilution, while bulls characterize the drop as a buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid a reported major Binance security breach, with traders debating whether shaken confidence in exchanges and possible withdrawals could add selling pressure. Others argue Bitcoin has held up relatively well and view the decline as a buying opportunity, while the breachs broader impact remains uncertain.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Concern about the Nov. 30 IPO lockup expiration and potential insider selling is weighing on QNT, alongside a sharp selloff. Traders are split between expecting continued pressure and arguing that Quantinuums technical progress, Oracle partnership and federal funding support the longer-term case.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TNXP Stock Rising Today?

Equity

Tonix announced a second commercial payer agreement for Tonmya, its fibromyalgia treatment.

Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA

Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial payer agreement for fibromyalgia drug TONMYA.read more...

TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal

The company announced a new agreement with a major group purchasing organization which opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S.

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.read more...

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD Cowen

TD Cowen raised Tonix Pharmaceuticals to a "strong-buy" rating in a report on Tuesday...

Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-tonix-pharmaceuticals-holding-corp-stock...

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug

The company said on Friday that it now expects a net loss for the first quarter of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell

Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from...

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>The new agreement opens up access to about 17 million additional insured Americans.</li><li>Tonmya is the first FDA-approved treatment for fibromyalgia in adults in more than 15 years.</li><li>Tonix also expects to have Lyme disease drug supply ready by early 2027.</li></ul>Tonix Pharmaceuticals (TNXP) shares gained on Monday after the firm announced a crucial update to its fibromyalgia treatment, Tonmya, which expands coverage to roughly 52 million people in the U.S.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> was up 5% at the time of writing.<h2 class="st-heading-2">New Agreement Opens Up Market For Tonmya</h2>Tonix announced a second commercial payer agreement for Tonmya, adding access to about 17 million more insured Americans. This represents about 29% of the U.S. commercial insurance market.“Existing treatments are limited by tolerability and side effects. Tonmya is a first-in-class, non-opioid analgesic designed for daily bedtime administration and long-term use,” said CEO Seth Lederman.<h2 class="st-heading-2">First FDA-Approved Fibromyalgia Drug In 15 Years</h2>Tonmya, launched in November 2025, is the first FDA-approved treatment for fibromyalgia in adults in more than 15 years. The non-opioid therapy is taken at bedtime and is designed for the long-term management of chronic pain associated with the condition, which affects millions of Americans, particularly women.The expansion follows Tonix’s first commercial coverage deal announced in May, which provided access to about 35 million people.<h2 class="st-heading-2">TNXP’s Lyme Disease Treatment In Focus</h2>Investors are also keeping an eye on updates regarding the TNX-4800, Tonix’s experimental antibody treatment designed to prevent Lyme disease.The company plans to start a Phase 2 study using two injections over one season to test protection against the disease for six months. Tonix expects to have drug supply ready in early 2027 and plans additional studies, including a human challenge trial, in 2028.<h2 class="st-heading-2">Retail’s Take On TNXP</h2>Retail sentiment surrounding TNXP on Stocktwits remained in the ‘bullish’ zone over the past 24 hours. TNXP was also among the top trending tickers on the platform.One user called this the “most important update” since the drug’s approval.<stembedurl>https://stocktwits.com/carronsbfc/message/655724749</stembedurl>The stock has crashed around 34% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-ai-stock-is-down-35-since-ipo-but-analysts-see-70-upside-potential-for-nvidia-challenger/cZ0v5STR7GJ">This New AI Stock Is Down 35% Since IPO – But Analysts See 70% Upside Potential For Nvidia Challenger</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.10
Prev Close	$5.28
Open	$5.18
Dividend Yield	0.00%
50-Day Moving Average	$9.53
Beta	1.45
Avg. Volume	431,335.42
PE Ratio	-0.39

52-Week High	$20.56
52-Week Low	$4.96
Market Capitalization	$87.47M
EPS (Annual)	-$14.57
Price to Book	0.39
Revenue Per Employee	$92,302.82

Feed

News

Sentiment

Earnings

Fundamentals

Info

TNXP Fundamentals